Research dossier
Clinical research on Serrapeptase
7 trials reviewed across 4 indications.
Strongest evidence
Post-surgical swelling (dental/oral)
Mechanism
Localized reduction of post-operative edema, plausibly via proteolytic breakdown of inflammatory exudate at the surgical site.
This is serrapeptase's least-bad use case. A modern RCT (n=133) after third-molar surgery showed modest reductions in swelling and trismus by day 4 — but no effect on pain. A small, short-term, local benefit, not a systemic anti-inflammatory validation.
Even the best signal is modest, short-lived, and limited to local post-surgical edema. It did not reduce pain, and corticosteroids/NSAIDs remain better-evidenced for surgical inflammation.
Trials cited
Serratiopeptidase after impacted third molar surgery
mixed · RCT
Tamimi et al., 2021, BMC Oral Healthn=133A modern, reasonably sized RCT (n=133). Serratiopeptidase modestly reduced swelling and trismus by day 4 versus placebo (both p<0.001) — but produced NO significant difference in pain. The most credible positive signal for serrapeptase, in a narrow surgical context, and even here the analgesic claim failed.
Local post-surgical edema is one of the few settings with any decent serrapeptase signal — and it's modest, short-term, and didn't touch pain. This does not validate the systemic 'dissolves inflammation everywhere' marketing.
Systemic anti-inflammatory effect
Mechanism
Serrapeptase is a proteolytic enzyme originally isolated from silkworm gut bacteria. The pitch is that, absorbed intact, it breaks down inflammatory proteins and edema fluid throughout the body. The problem: it is itself a protein, so oral dosing faces digestion, and there is no good human evidence it reaches the circulation as an active enzyme in meaningful amounts.
The systemic anti-inflammatory claim rests on old, small, mostly manufacturer-era trials (Mazzone 1990) and uncontrolled pilots confounded by NSAID co-treatment (Panagariya 1999). The 2013 systematic review judged it 'not rational' to prescribe, and Japan's regulator could not confirm efficacy — leading Takeda to withdraw it. Treat the 'natural anti-inflammatory enzyme' framing as marketing.
No rigorous, independent, modern trial establishes a systemic anti-inflammatory benefit. The cleanest data are negative or regulatory-withdrawal.
Serratiopeptidase — systematic review of the evidence
Null · Systematic review
Bhagat et al., 2013, International Journal of SurgeryThe key skeptical review. After searching Cochrane, PubMed, MEDLINE and ClinicalTrials.gov, the authors concluded that the existing trials are few and of unclear scientific credibility, and that 'until there is clear scientific evidence,' it is NOT rational to prescribe serratiopeptidase as an anti-inflammatory, analgesic, or anti-atherosclerotic agent. This is the honest summary of the field.
A narrative/systematic review rather than a pooled meta-analysis. Its central conclusion — that the evidence base is too thin and low-quality to justify use — remains the dominant verdict.
Takeda withdrawal of Danzen (serrapeptase) in Japan
negative · Observational
Takeda Pharmaceutical post-market re-evaluation, 2011 (reported via Japanese PMDA / pharmaceutical press)The single most damning real-world data point. After Japan's regulatory re-evaluation, the double-blind studies comparing Danzen (serrapeptase) to placebo found no statistically significant difference. Rather than run the additional confirmatory trials regulators required, Takeda voluntarily withdrew the product in 2011. Singapore later phased out serrapeptase medicinal products citing the same lack of evidence.
This is a regulatory/manufacturer action, not a single published RCT — but it reflects placebo-controlled data that failed to confirm efficacy in the country where serrapeptase was most established. The decision to withdraw rather than re-test speaks volumes.
Serratia peptidase for ENT inflammation
positive · RCT
Mazzone et al., 1990, Journal of International Medical Researchn=193Industry-fundedThe most-cited 'positive' serrapeptase trial. A multicentre double-blind RCT (n=193) reported faster and greater symptom relief (pain, secretions, nasal obstruction) versus placebo over about a week in acute/chronic ENT conditions. This single Italian trial underpins much of the 'anti-inflammatory enzyme' marketing.
From 1990, short (7–8 days), uses subjective clinician-rated symptom scales for self-limiting ENT conditions, and dates to the manufacturer-driven era of serrapeptase research. A genuinely positive trial, but old, soft-endpoint, and not independently replicated at quality.
Serratiopeptidase for carpal tunnel syndrome (pilot)
positive · Pilot
Panagariya & Sharma, 1999, Journal of the Association of Physicians of Indian=20A small open-label pilot (n=20) reporting 65% clinical improvement in carpal tunnel syndrome. Routinely cited as evidence serrapeptase 'reduces inflammation' — but it is tiny, uncontrolled, and patients were co-treated with the NSAID nimesulide, so any benefit cannot be attributed to serrapeptase.
n=20, open-label, no placebo arm, and confounded by concurrent NSAID use. Hypothesis-generating at best; not evidence of efficacy.
Mucolytic / respiratory (clearing mucus)
Mechanism
Proposed to thin and break down mucus and inflammatory secretions in the airways — the basis for its long use in Japan for bronchitis and sinusitis.
The mucolytic claim is the one most directly tested and most clearly failed. An open-label airway RCT (Nakamura 2003) found no convincing benefit and called for serrapeptase to be eliminated from practice, and the only 'positive' respiratory data (Shah 2024, IPF) come from a proprietary multi-enzyme blend on subjective endpoints. Reviews rate the respiratory evidence insufficient.
Not supported as a mucolytic. Standard respiratory therapies have real evidence; serrapeptase does not.
Serrapeptase for chronic airway disease (sputum)
Null · RCT
Nakamura et al., 2003, Respirologyn=29An open-label randomized trial (n=29) testing serrapeptase's marquee 'mucolytic' claim. Despite being unblinded — a design that usually FAVORS the active drug — it found no convincing benefit, and the authors concluded the proteolytic enzyme serrapeptase 'should be eliminated from clinical practice.'
Small (n=29) and open-label. But the negative result despite an unblinded design that should have inflated any effect makes the null especially telling.
Systemic enzyme supplement (incl. serrapeptase) in idiopathic pulmonary fibrosis
mixed · RCT
Shah et al., 2024, Diseases (MDPI)n=100Industry-fundedA recent RCT (n=100) reporting improved breathlessness and symptom scores versus placebo in IPF. Promoted as evidence serrapeptase 'helps lung fibrosis' — but the intervention was a proprietary MULTI-enzyme/vitamin blend, not isolated serrapeptase, all subjective questionnaire endpoints, with no change in objective lung function reported.
The serrapeptase contribution is impossible to isolate from nattokinase, other enzymes, antioxidants and vitamins in the commercial Serracor-NK/Serra Rx260 products. Subjective-symptom endpoints only. Reads as a manufacturer proof-of-concept, not proof that serrapeptase works for fibrosis.
'Dissolving' plaque, clots, scar tissue or fibroids
Mechanism
Internet claims hold that serrapeptase's fibrinolytic activity 'digests' arterial plaque, blood clots, scar tissue, fibroids, and cysts. This extrapolates from in-vitro and animal observations of proteolysis.
There is no human RCT showing serrapeptase dissolves arterial plaque, breaks down clots, shrinks fibroids, or removes scar tissue. These are the boldest serrapeptase claims and they have the least support — pure extrapolation from test-tube proteolysis, flagged by the 2013 review as unsupported and not rational to act on.
Unsupported in humans. Do not use serrapeptase in place of evidence-based treatment for cardiovascular disease, clots, or gynecologic conditions.
Serratiopeptidase — systematic review of the evidence
Null · Systematic review
Bhagat et al., 2013, International Journal of SurgeryThe key skeptical review. After searching Cochrane, PubMed, MEDLINE and ClinicalTrials.gov, the authors concluded that the existing trials are few and of unclear scientific credibility, and that 'until there is clear scientific evidence,' it is NOT rational to prescribe serratiopeptidase as an anti-inflammatory, analgesic, or anti-atherosclerotic agent. This is the honest summary of the field.
A narrative/systematic review rather than a pooled meta-analysis. Its central conclusion — that the evidence base is too thin and low-quality to justify use — remains the dominant verdict.
3 forms of Serrapeptase compared
Enteric-coated serrapeptase
Enteric coating is meant to protect the enzyme from stomach acid, but intact systemic absorption of an active enzyme in humans is unproven
Best forThe form used to argue serrapeptase survives digestionEnteric coating addresses gastric acid but not the core question: even if it reaches the small intestine, there's little human evidence a large protein enzyme is absorbed intact and active into the bloodstream. Coating is a plausibility patch, not proof of systemic activity.
Uncoated serrapeptase
Largely digested like any dietary protein; systemic enzymatic activity unproven
Best forGeneric 'anti-inflammatory enzyme' supplementsWithout enteric protection, even more of the enzyme is exposed to stomach acid and digestion. As with the coated form, there is no convincing human evidence of meaningful intact absorption.
SPU-standardized serrapeptase
Standardizes enzyme activity units, not absorption
Best forLabeling by activity (Serrapeptase Units)Doses are labeled in SPU (serrapeptase units); roughly 1 mg ≈ 2,000 SPU, so the RCT-era ~10 mg three times daily corresponds to about 60,000 SPU/day. Higher SPU on a label says nothing about whether the enzyme reaches your tissues intact.
Are you deficient? Symptoms, risk groups, lab tests
Serrapeptase is not a nutrient and not made by the human body — it is a bacterial enzyme (from Serratia in the silkworm gut) taken as a drug-like supplement. There is no such thing as serrapeptase deficiency; it is taken for a claimed pharmacological effect, not to correct a shortfall.
Side effects and drug interactions
Side effects
Eosinophilic pneumonia / lung injury
Rare
Multiple Japanese case reports describe serrapeptase-induced acute eosinophilic pneumonia and pneumonitis — fever, cough, dyspnea, and lung infiltrates that resolve after stopping the drug (and with steroids). Drug lymphocyte stimulation tests were positive for serrapeptase. Rare, but serious and well documented.
GI upset
Uncommon
Nausea, stomach discomfort, poor appetite, and occasional diarrhea — the most common complaints.
Skin reactions
Uncommon
Rash and other cutaneous reactions have been reported, consistent with an immune/allergic response to a foreign bacterial protein.
Bleeding risk (theoretical/additive)
Uncommon
Because serrapeptase is promoted as 'fibrinolytic,' there is a theoretical concern it could add to the bleeding risk of anticoagulant or antiplatelet drugs. Evidence is weak, but caution is warranted.
Drug interactions
Combined-effect risk
warfarindirect oral anticoagulants (apixaban, rivaroxaban)antiplatelets (aspirin, clopidogrel)fish oil / high-dose omega-3Serrapeptase's claimed fibrinolytic activity could theoretically add to the bleeding risk of blood-thinning drugs and supplements.
Avoid or use only with medical supervision if you take anticoagulants or antiplatelet drugs, and stop before surgery.
Other
antibioticsOlder marketing claimed serrapeptase enhances antibiotic penetration into tissues; this is not established in robust human trials.
Do not rely on serrapeptase to 'boost' antibiotics. Take antibiotics exactly as prescribed.
Other critical caveats
- Takeda WITHDREW serrapeptase (Danzen) in Japan in 2011 after regulatory re-evaluation: double-blind trials found no significant difference from placebo, and the company chose to pull the product rather than run the confirmatory studies regulators required. Singapore subsequently phased it out for the same reason.
- Claims that serrapeptase 'dissolves' arterial plaque, blood clots, scar tissue, fibroids, or cysts in humans have NO supporting clinical trials. They are extrapolated from test-tube proteolysis. Do not substitute serrapeptase for evidence-based medical treatment.
- Oral absorption of an intact, active enzyme is dubious. Serrapeptase is a large protein and, like dietary protein, is subject to digestion. There is no convincing human evidence that meaningful amounts reach the bloodstream still enzymatically active.
- Real safety signals exist: rare but serious case reports of serrapeptase-induced eosinophilic pneumonia/pneumonitis, and a theoretical additive bleeding risk with anticoagulant or antiplatelet drugs. Stop before surgery and avoid combining with blood thinners without medical guidance.
- The supportive trials are old, small, often Italian or Japanese, frequently from the manufacturer era, and use soft subjective endpoints. The 2013 systematic review concluded it is not rational to prescribe serrapeptase.
Frequently asked
Does serrapeptase actually work as an anti-inflammatory?
The honest answer is: probably not in any reliable, systemic way. The supportive trials are old, small, and mostly from the manufacturer era, a 2013 systematic review concluded it's 'not rational' to prescribe it, and Japan's regulator could not confirm efficacy — which led Takeda to withdraw the original product in 2011. The one half-decent modern signal is modest reduction of swelling after dental surgery, and even there it didn't reduce pain.Can serrapeptase dissolve arterial plaque, scar tissue, or blood clots?
No human trials support this. These are the boldest claims made for serrapeptase and they have the least evidence — they're extrapolated from what the enzyme does in a test tube, not from controlled studies in people. Do not use serrapeptase in place of real treatment for heart disease, clots, fibroids, or scarring.Why was serrapeptase withdrawn in Japan?
In 2011, after a regulatory re-evaluation, the double-blind placebo-controlled studies of Danzen (serrapeptase) failed to show a statistically significant benefit over placebo. Rather than run the additional confirmatory trials regulators required, Takeda voluntarily withdrew it. Singapore later phased out serrapeptase medicinal products on similar grounds. This is the strongest single signal that it doesn't work.Is serrapeptase absorbed when you swallow it?
That's a real open question. Serrapeptase is a large protein, and proteins are broken down by digestion. Enteric coating is meant to protect it from stomach acid, but even then there's little convincing human evidence that meaningful amounts of the intact, active enzyme reach the bloodstream. If it isn't absorbed intact, the systemic 'dissolves inflammation everywhere' premise falls apart.Is serrapeptase safe?
It's usually tolerated, but not risk-free. There are rare but serious case reports of serrapeptase causing eosinophilic pneumonia (lung inflammation), plus GI upset and skin reactions. Because it's marketed as 'fibrinolytic,' there's also a theoretical added bleeding risk — avoid it with anticoagulants or antiplatelet drugs and stop before any surgery.
References
- 01Bhagat et al., 2013 — Serratiopeptidase: a systematic review of the existing evidence (Int J Surg)
- 02Nakamura et al., 2003 — Serrapeptase in chronic airway disease (Respirology)
- 03Tamimi et al., 2021 — Serratiopeptidase after impacted third molar surgery (BMC Oral Health)
- 04Drugs.com — Serrapeptase (professional monograph)
- 05Examine.com — Serrapeptase
Last reviewed2026-05-24